NCCN Announces Funding for a Prostate Cancer Research Project
NCCN Announces Funding for a Prostate Cancer Research Project
"This work will enhance our understanding of how to better care for individuals with prostate cancer."The National Comprehensive Cancer Network's Oncology Research Program's grant will advance scientific knowledge of hematologic toxicity of PARPi in the treatment of patients with prostate cancer.
國家綜合癌症網絡的腫瘤研究項目的資助將推進關於PARPi在前列腺癌患者治療中血液毒性的科學知識。
PLYMOUTH MEETING, Pa., Dec. 11, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) today announced funding of a project that will underpin innovative research on optimal management of side effects secondary to treatment with poly ADP ribose polymerase inhibitors (PARPi). The award is supported by Pfizer Global Medical Grants and Partnerships.
普利茅斯會議，賓夕法尼亞州，2024年12月11日 /PRNewswire/ -- 國家綜合抗癌網絡(NCCN)腫瘤研究項目(ORP)今天宣佈資助一個項目，該項目將支持關於多聚腺苷二磷酸核糖聚合酶抑制劑(PARPi)治療副作用的最佳管理的創新研究。該獎項由輝瑞全球醫療撥款和合作夥伴關係支持。
PARPi treatment is associated with hematologic toxicity, often leading to dose modification, treatment interruption, discontinuation, or the need for enhanced supportive care interventions. Anemia is the most common side effect associated with PARPi in patients with metastatic castration-resistant prostate cancer (mCRPC), with about a quarter of patients reporting serious anemia shortly after PARPi initiation. The use of PARPi is expected to rise in the coming years, and their combination with other agents is already being examined in earlier disease settings.
PARPi治療與血液毒性相關，常常導致劑量調整、治療中斷、停藥或需要增強的支持性護理干預。貧血是與PARPi相關的最常見副作用，在轉移性去勢抵抗性前列腺癌(mCRPC)患者中，約有四分之一的患者在PARPi治療開始後不久報告嚴重貧血。預計在未來幾年內PARPi的使用將會增加，目前正在早期疾病階段研究與其他藥物的聯合應用。
"This work will enhance our understanding of how to better care for individuals with prostate cancer."
"這項工作將增強我們對如何更好地照顧前列腺癌患者的理解。"
In the mCRPC population, there can be additional challenges due to advanced age, reduced bone strength, other co-existing medical conditions, as well as significant prior treatments that add to the risk of toxicities.
在mCRPC人群中，由於年齡增大、骨骼強度降低、其他共存的醫療狀況以及顯著的先前治療等因素，可能會面臨額外的挑戰，這增加了毒性的風險。
"The aim of this research is to advance our understanding and ability to reduce adverse effects from PARPi alone or in combination with other treatments for patients with prostate cancer," explained Crystal S. Denlinger, MD, Chief Executive Officer, NCCN. "Congratulations to this remarkable investigator. This work will enhance our understanding of how to better care for individuals with prostate cancer."
"這項研究的目的是提高我們對PARPi單獨使用或與其他治療聯合使用的副作用降低的理解和能力，" NCCN首席執行官Crystal S. Denlinger博士解釋說。"恭喜這位傑出的研究者。這項工作將增強我們對如何更好地照顧前列腺癌患者的理解。"
The selected project will be led by:
該項目由以下人員領導：
-
David Link, MD, Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
- Impact of Germline BRCA1/2 Mutations on PARPi-induced Anemia
- 大衛·林克醫學博士，巴恩斯-猶太醫院西特曼癌症中心及華盛頓大學醫學院
- 種系BRCA1/2突變對PARPi誘導貧血的影響
"We are really pleased to support this important research and to collaborate with the National Comprehensive Cancer Network. Working with organizations like NCCN gives us the opportunity to accelerate and improve health outcomes for prostate cancer patients. We're working every day to reduce healthcare disparities by leading and contributing to a variety of initiatives, programs, partnerships, and investments including our support of this initiative," said Maureen Doyle-Scharff, PhD, FACEhp, Head of Global Medical Grants and Partnerships, Pfizer.
「我們非常高興能支持這項重要研究，並與全國綜合癌症網絡（NCCN）合作。與NCCN這樣的組織合作使我們有機會加速並改善前列腺癌患者的健康結果。我們每天都在努力通過主導和參與各種倡議、項目、合作伙伴關係和投資，包括我們對這個倡議的支持，來減少醫療差距，」輝瑞全球醫療撥款和夥伴關係負責人莫琳·道伊爾-夏夫博士說。
Proposals were peer reviewed by a Scientific Review Committee, which consisted of leading expert oncologists from NCCN Member Institutions. The selected project is set to be completed within two years.
提案由科學審查委員會進行同行評審，該委員會由NCCN會員機構的領先腫瘤專家組成。所選項目計劃在兩年內完成。
The NCCN ORP fosters innovation and knowledge discovery that improve the lives of people with cancer and supports preclinical, translational, and clinical research and quality improvement projects in oncology at NCCN Member Institutions. In an effort to improve collaboration in cancer research, the NCCN ORP also maintains a shared resources website, an informed consent database, and points to consider on the best practices for biorepositories, registries, and databases. For more information, visit NCCN.org/orp.
NCCN ORP促進創新和知識發現，改善癌症患者的生活，並支持NCCN會員機構的臨床前、轉化和臨床研究及質量改進項目。爲了改善癌症研究中的合作，NCCN ORP還維護一個共享資源網站、一個知情同意數據庫，並提供關於生物樣本庫、登記處和數據庫最佳實踐的考慮要點。欲了解更多信息，請訪問NCCN.org/orp。
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network (NCCN) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to defining and advancing quality, effective, equitable, and accessible cancer care so all people can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) provide transparent, evidence-based, expert consensus-driven recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit NCCN.org for more information.
關於全國綜合癌症網絡
全國綜合癌症網絡（NCCN）是一個非營利性聯盟，由領先的癌症中心組成，致力於患者護理、研究和教育。NCCN致力於定義和推進高質量、有效、公平和可及的癌症護理，以便讓所有人過上更好的生活。NCCN腫瘤臨床實踐指南（NCCN指南）提供透明的、基於證據的、專家共識驅動的癌症治療、預防和支持服務的建議；它們是癌症管理中公認的臨床方向和政策標準，也是任何醫學領域中最全面和最常更新的臨床實踐指南。NCCN患者指南提供專家癌症治療信息，以通知和賦權患者及照顧者，得到了NCCN基金會的支持。NCCN還推進繼續教育、全球倡議、政策，以及腫瘤學領域的研究合作與出版。欲了解更多信息，請訪問NCCN.org。
Media Contact:
Rachel Darwin
267-622-6624
[email protected]
媒體聯繫人：
瑞秋·達爾文
267-622-6624
[email protected]
SOURCE National Comprehensive Cancer Network
來源：國家綜合抗癌網絡
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
想讓貴公司的資訊在PRNEWSWIRE.COM上特色展示嗎？
譯文內容由第三人軟體翻譯。